Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Antireticular cytotoxic serum Antireticular cytotoxic serum Anti-reticular Cytotoxic Serum is made from the blood of a rabbit that has been injected with homogenized cadaver spleen and rib marrow. In small quantities it can aid animal growth, but is toxic in large doses. It was first developed by Alexander A. Bogomolets in 1936. "It was a "miracle" that Professor Bogomolets made dying people walk with blood of cadavers circulating through their bodies, or hoped to extend our life-span for 150 years with the help of the A.C.S serum" - Red Miracle: The Story of Soviet Medicine by Edward Podolsky "World Book Encyclopedia", 1967 Edition,